The FDA is launching a 120-day pilot program aimed at reducing online transactions involving unapproved opioids, according to a June 8 news release.
Three internet registries will participate in the program: Neustar, Verisign and Public Interest Registry. The FDA will notify the registries when it sends a warning letter to a website operator and the operator does not respond sufficiently or within the allotted time frame. The internet registries will assess the next course of action in each case, which may lead to blocking or domain suspension.
The National Telecommunications and Information Administration is partnering with the FDA on this project, and the two agencies will jointly assess its effectiveness.